Management of Anaphylaxis Associated with Vaccination for COVID-19 in Children.
Dokkyo Journal of Medical Sciences
; 49(2):75-84, 2022.
Article
in Japanese
| EMBASE | ID: covidwho-2272391
ABSTRACT
By September 2022, approximately 2. 88 million doses of COVID-19 mRNA vaccine had been administered in Japanese children, and 9 cases of vaccine-related anaphylaxis had been reported. Of these, 2 cases were determined to be definite anaphylaxis by expert review, for an incidence rate of 0. 7 cases per million doses. This is equivalent to the incidence of anaphylaxis from adverse reactions to existing vaccines. If anaphylaxis occurs, pediatricians should administer an intramuscular injection of adrenaline, the first choice of treatment for anaphylaxis. The allergen contained in mRNA vaccines is likely to be polyethylene glycol(PEG). Therefore, we must be cau-tious in our decision to vaccinate individuals with a history of allergic reactions to PEG-containing agents. However, since no clinical test has been established to confirm allergic reactions to PEG prior to vaccination, efforts are being made to identify high-risk patients by questionnaire. It is necessary for each facility to clearly state how to respond to anaphylaxis and share information among staff so that treatment can be reliably administered in the event of anaphylaxis.Copyright © 2022, Dokkyo University School of Medicine. All rights reserved.
Search on Google
Collection:
Databases of international organizations
Database:
EMBASE
Topics:
Vaccines
Language:
Japanese
Journal:
Dokkyo Journal of Medical Sciences
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS